The efficacy of durvalumab in locally advanced lung carcinoma
Abstract
Background: The integration of durvalumab, an immune checkpoint inhibitor, as consolidation therapy following platinum-based chemoradiotherapy has redefined the standard of care for patients with stage III, unresectable non-small cell lung cancer (NSCLC) who have not experienced disease progression. Although clinical trials, particularly the PACIFIC study, demonstrated significant improvements in survival outcomes, real-world data are still needed to validate these findings in routine clinical settings. This retrospective study aimed to evaluate the real-world efficacy of durvalumab in patients treated at the Institute for Pulmonary Diseases of Vojvodina, focusing on key clinical endpoints, progression-free survival (PFS), duration of clinical benefit (DoCB), and overall response rate (ORR), while exploring the influence of demographic and tumor-related factors.
Methods: The study included 25 patients with stage III NSCLC, ECOG 0–1, and PDL-1 expression ≥1%, who received durvalumab after chemoradiotherapy. The treatment responses were evaluated using iRECIST criteria. The Kaplan-Meier analysis was used for survival metrics, and univariate Cox regression assessed the impact of histology, smoking status, PDL-1 expression, gender, and ECOG status.
Results: A partial response was achieved in 36% of the patients, stable disease in 40%, and progression in 24%, with an ORR of 36%. The mean PFS was 19.8 months, and DoCB 25 months. Although the adenocarcinoma subtype, female gender, lower pack-year index, and higher PDL-1 expression suggested more favorable outcomes, no statistically significant differences were found.
Conclusion: These findings confirm the clinical benefit of durvalumab consolidation in real-world practice, with outcomes comparable to pivotal trials. Despite the small sample size, the observed trends highlight potentially relevant prognostic markers. Expanding the patient cohort and extending the follow-up will further clarify these associations and support the evidence-based personalization of the NSCLC treatment.
References
Orosz Z, Kovács Á. The role of chemoradiotherapy and immunotherapy in stage III NSCLC. Pathol Oncol Res. 2024;30(1):1611716.
Miao D, Li W, Huang X, Wang L, Zhang Y, Chen G, et al. Management of locally advanced non-small cell lung cancer: State of the art and future directions. Cancer Commun (Lond). 2023;43(12):12505.
Perin B. Nemikrocelularni karcinom bronha. In: Popović S, Obradović D, editors. Interna medicina I. Pulmologija i kardiologija. Prvo izdanje. Novi Sad: Medicinski fakultet Novi Sad; 2022. p. 71–83.
Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42(10):12359.
Deshpand R, Chandra M, Rauthan A. Evolving trends in lung cancer: Epidemiology, diagnosis, and management. Indian J Cancer. 2022;59:90–105.
Li Y, Wang R, Zhang Y, Li X, Liu J, Xu W, et al. Efficacy and safety of immune checkpoint inhibitors for advanced nonsmall cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis. Chin Med J (Engl). 2023;136(18):2064–72.
Socinski MA, Goldman JW, El-Hariry I, Koczywas M, Horn L, Garon EB, et al. Durvalumab after concurrent chemoradiotherapy in elderly patients with unresectable stage III non–small–cell lung cancer (PACIFIC). Clin Lung Cancer. 2021;22(6):549–61.
Mazieres J, Remon J, Greillier L, Barlesi F, Novello S, Popat S, et al. MET Exon 14 skipping in NSCLC: A systematic literature review of epidemiology, clinical characteristics, and outcomes. Clin Lung Cancer. 2023;24(6):483–97.
Filippi AR, Badellino S, Ceccarelli M, Franco P, Ruo Redda MG, Levis M, et al. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R. ESMO Open. 2024;9(6):103464.
Nakamichi S, Yamamoto N, Seto T, Sugawara S, Yokouchi H, Tamura T, et al. Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study). Clin Cancer Res. 2024;30(4):1104–10.
Verschueren MV, Maes M, Surmont V, Van Dam P, Decoster L, Gervais R, et al. Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: Real-world outcomes versus clinical trial results. Immunotherapy. 2023;15(11):839–51.
Taugner J, Käsmann L, Eze C, Roengvoraphoj O, Dantes M, Gennen K, et al. Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC leads to significant improvement of local-regional control and overall survival in the real-world setting. Cancers (Basel). 2021;13(7):1613.
Mouri A, Yoneda T, Ogawa H, Kato T, Nishikawa S, Hashimoto H, et al. A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A. ESMO Open. 2024;9(10):103939.
Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. J Clin Oncol. 2022;40(13):1301–11.
Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste J, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial. J Thorac Oncol. 2021;16(1):1–9.
Jazieh K, Jones L, Alomari AK, Soudy H, Rahman N, Bittar H, et al. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. J Immunother Cancer. 2022;10:e003778.
Scott AJ, Duffy M, O’Byrne K, Gilligan D, Steele N, Franks K, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29.
Naidoo J, Liu SV, Papadopoulos KP, Besse B, Cho BC, Hochmair MJ, et al. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC. J Thorac Oncol. 2023;18(5):123–30.
Faivre-Finn C, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste J, Spigel DR, et al. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer. 2020;150:97–106.
Jazieh K, AlShammari S, AlFarsi A, Almutairi S, Aljurf M, Al-Foheidi M, et al. Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab. Transl Lung Cancer Res. 2021;10(6):2466–76.
Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020;31(6):902–9.
Delgado A, Guddati AK. Clinical endpoints in oncology - a primer. Am J Cancer Res. 2021;11(4):1121–31.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e152.
Preti BTB, Corrêa EP, Batista MN, da Silva RA, Oliveira RC, Rocha PM, et al. Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer. Curr Oncol. 2023;30:7713–21.
Aredo JV, Padda SK, Neal JW, Wakelee HA, West HJ, Ramalingam SS, et al. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. J Thorac Oncol. 2021;16(5):771–80.
